Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.
Authors not listed
University Hospital, Strasbourg, France · 2012
Abstract
The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2012). Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease. <em>University Hospital, Strasbourg, France</em>. https://clinicaltrials.gov/study/NCT00412048
Vancouver
Anonymous. Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease. University Hospital, Strasbourg, France. 2012.
BibTeX
@misc{anon2012Evalua,
title = {Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.},
author = {Anonymous},
journal = {University Hospital, Strasbourg, France},
year = {2012},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Medical College of Wisconsin 2009
Open access · US-GOV
A Composite MR Neuroimaging Marker for Alzheimer's Disease
University of California, Davis 2022
Open access · US-GOV
Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease
Poitiers University Hospital 2023
Open access · US-GOV
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
Annovis Bio Inc. 2020
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
Beijing Friendship Hospital 2015
Open access · US-GOV
Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study
Aleksandra Stark 2017
Open access · US-GOV